Evidence map›Paper›PMID 35106404›Full record

ArticleAmerican journal of ophthalmology case reports2022

Persistent mass after treatment for orbital rhabdomyosarcoma.

Jonathan C Siktberg, Alexandra E Kovach, Scott C Borinstein, Hernan Correa, Frank W Virgin, Rachel K Sobel

Open access · goldAbstract readCase Reports
In one paragraph

Article in American journal of ophthalmology case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jonathan C SiktbergVanderbilt University School of Medicine, 1161 21st Ave S # D3300, Nashville, TN, USA, 37232.
Alexandra E KovachDivision of Pediatric Pathology, Department of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center, 1211 Medical Center Drive, Nashville, TN, USA, 37232.
Scott C BorinsteinDepartment of Pediatrics, Division of Pediatric Hematology/Oncology, Vanderbilt University Medical Center, 2220 Pierce Ave, Nashville, TN, USA, 37232.
Hernan CorreaDivision of Pediatric Pathology, Department of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center, 1211 Medical Center Drive, Nashville, TN, USA, 37232.
Frank W VirginDepartment of Otolaryngology, Vanderbilt University Medical Center, 1211 Medical Center Drive, Nashville, TN, USA, 37232.
Rachel K SobelDepartment of Ophthalmology and Visual Sciences, Vanderbilt University Medical Center, 2311 Pierce Ave, Nashville, TN, USA, 37232.
Vanderbilt University Medical Center · USVanderbilt University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo report a case of orbital rhabdomyosarcoma and highlight the treatment approach to the dilemma of a residual mass. OBSERVATIONS: An eleven-year-old boy was diagnosed with Stage 1, Group III embryonal rhabdomyosarcoma in the orbit. After completing a 24-week treatment regimen of chemotherapy and radiation, imaging showed a large persistent mass with erosion through the medial wall. It was uncertain whether the erosion was due to radiation osteonecrosis or to advancing tumor, creating a treatment dilemma for the providers. A repeat biopsy was planned. During the procedure, the mass was completely excised due to ease of removal, and the biopsy showed completely treated tumor. MRI surveillance at four years follow up showed that the patient remains tumor-free. CONCLUSIONS AND IMPORTANCE: Rhabdomyosarcoma was once a disease with a very poor outcome, but advances in imaging, chemotherapy, and radiation therapy have improved the prognosis of these patients. What was once a surgical disease treated with morbid resection is now predominantly a medical disease diagnosed with biopsy and treated with chemotherapy and radiation. However, such patients may have a residual mass after completing treatment. This situation presents a challenge, as it may not be clear whether the persistent mass is active tumor or treated tumor. This report describes the presentation and management of such a case in the orbit and demonstrates that a residual orbital mass may remain and represent completely treated tumor.

Indexed as

BiopsyChemotherapyOrbitOrbital rhabdomyosarcomaPersistent massRhabdomyosarcoma

Identifiers

PMID35106404
PMCPMC8789529
OpenAlexW4205106461

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.